Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

NCT04281485

Active Not RecruitingPhase 3

Sponsor: Pfizer

Conditions: Duchenne Muscular Dystrophy

Interventions: PF-06939926, Placebo, Placebo, PF-06939926

Countries: United States, Australia, Belgium, Canada, France, Germany, Israel, Italy

The study will evaluate the safety and efficacy of gene therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study with two thirds of participants assigned to gene therapy. The one third of participants who are randomized to the placebo arm will have an opportunity for treatment with gene therapy at the beginning of the second year.

Eligibility overview

Sex: MALE

Age: 4 Years to 7 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Key inclusion criteria:

1. Confirmed diagnosis of Duchenne muscular dystrophy by prior genetic testing
2. Receiving a stable daily dose (at least 0.5 mg/kg/day prednisone or prednisolone, or at least 0.75 mg/kg/day deflazacort) for at least 3 months prior to Screening
3. Ambulatory, as assessed by protocol-specified criteria

Key exclusion criteria:

1. Positive test performed by Pfizer for neutralizing antibodies to AAV9
2. Any treatment designed to increase dystrophin expression within 6 months prior to screening (e.g., Translarna™, EXONDYS 51™, VYONDYS 53™)
3. Any prior treatment with gene therapy
4. Any non-healed injury that may impact functional testing (eg NSAA)
5. Abnormality in specified laboratory tests, including blood counts, liver and kidney function
6. Any of the following genetic abnormalities in the dystrophin gene:

   1. Any mutation (exon deletion, exon duplication, insertion, or point mutation) affecting any exon between exon 9 and exon 13, inclusive; OR
   2. A deletion that affects both exon 29 and exon 30;OR
   3. A deletion that affects any exons between 56-71, inclusive.
Locations (53)
  • Little Rock, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Los Angeles, California, United States
  • Gainesville, Florida, United States
  • Iowa City, Iowa, United States
  • Fairway, Kansas, United States
  • Kansas City, Kansas, United States
  • Kansas City, Kansas, United States
  • Kansas City, Kansas, United States
  • Kansas City, Kansas, United States
  • Prairie Village, Kansas, United States
  • Durham, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
  • Salt Lake City, Utah, United States
  • Salt Lake City, Utah, United States
  • Salt Lake City, Utah, United States
  • Seattle, Washington, United States
  • Westmead, New South Wales, Australia
  • Parkville, Victoria, Australia
  • Nedlands, Western Australia, Australia
  • Ghent, Belgium
  • Leuven, Belgium
  • Calgary, Alberta, Canada
  • London, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Toronto, Ontario, Canada
  • Nantes, France
  • Paris, France
  • Berlin, Germany
  • Essen, Germany
  • + 23 more on CT.gov